53rd ANNUAL SCIENTIFIC MEETING AUSTRALIAN AND · PDF fileAUSTRALIAN AND NEW ZEALAND SOCIETY OF...

4th – 6th September 2017Darwin Convention Centre | Northern Territory

AUSTRALIAN AND NEW ZEALAND

SOCIETY OF NEPHROLOGY (ANZSN)

53rd ANNUAL SCIENTIFIC MEETING

2 ANZSN | ANNUAL SCIENTIFIC MEETING

SPONSORS

GOLD SPONSORS

SILVER SPONSOR

BRONZE SPONSOR

PAD/PEN SPONSOR

BARISTA SPONSOR

NAME BADGE SPONSOR

DIETITIAN DAY SPONSORS

UPDATE COURSE SPONSOR

MEETING APP SPONSOR

3DARWIN, NT | 4 – 6 SEPTEMBER 2017

OFFICE BEARERS

PRESIDENTProfessor Jonathan Craig

PRESIDENT ELECTA/ Prof Nigel Toussaint

HONORARY EXECUTIVE OFFICERA/Prof Germaine Wong

TREASURERA/Professor Girish Talaulikar

COUNCILDr Katherine Barraclough

Dr Ross Francis

Dr Jaquelyn Hughes

Dr Joshua Kausman

Dr Murray Leikis

A/Prof David Mudge

LOCAL ORGANISING COMMITTEE CO-CHAIRSDr Paul Lawton

Dr Sandawana William Majoni

SCIENTIFIC PROGRAM AND EDUCATION COMMITTEEA/Professor Angela Webster (Chair)

Professor Francesco Ierino

A/Professor Sharon Ricardo

A/Professor Wai Lim

A/Professor Dr Gopi Rangan

Dr John Irvine

Dr Muh Geot Wong

Dr Robert MacGinley

A/Prof Greg Tesch

Dr Andrew Mallett

Dr Peter Trnka

Dr Martin Gallagher (2018 LOC)

ANZSNExecutive Officer

Ms Anna Golebiowski

Administrative Officer

Ms Jourdan Pinnell

PROFESSIONAL CONFERENCE ORGANISERConference Design Pty Ltd


On behalf of the Australian and New Zealand Society of Nephrology’s President, Jonathan Craig, the Scientific Program and Education Committee and the Local Organising Committee, we welcome you to the 53rd Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, to being held from 4th to 6th September 2017 in Darwin.

The Scientific Program and Education Committee, chaired by Associate Professor Angela Webster, has planned a first-rate program, around the theme “ Equity and Diversity”.

Expert international and national speakers will bring you the very latest advances and contemporary summaries in nephrological science and clinical care. As is now customary, this will be complemented by the pre-meeting ANZSN Update Course and the ANZSIN meeting afterwards.

Darwin is an exciting destination with much more to offer than just the headlines. We’re confident you’ll find your visit to Darwin memorable and enjoyable, both scientifically and socially.

Yours sincerely,

Dr. Paul Lawton & Dr. William MajoniCo-Chairs, Local Organising Committee

WELCOME


SPEAKERS

PLENARY SPEAKERS

A/Professor Camille KottonClinical Director, Transplant Infectious Disease and Immunocompromised Host Program, Massachusetts General Hospital

Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Professor Laura DemberProfessor of Medicine and Epidemiology at the University of Pennsylvania Perelman School of Medicine

Faculty Member, Renal-Electrolyte and Hypertension Division

Senior Scholar, Center for Clinical Epidemiology and Biostatistics

Professor Charmaine E LokProfessor of Medicine at the University of Toronto

Medical Director of both the multidisciplinary chronic kidney disease (CKD) and hemodialysis programs at the University Health Network-Toronto General Hospital

SEMINAR SPEAKERS

Dr Basu GopalDr Cara HildrethProfessor Karin Jandeleit-DahmProfessor Masaomi NangakuProfessor Carol Pollock

Professor Sharon RicardoDr Cherie StaynerProfessor Motoko YanagitaAssociate Professor Allison Tong


SOCIAL FUNCTIONS

Nephrology & Transplantation Update Course DinnerDate: Saturday 2 September 2017

Time: 6:30pm – 10:30pm

Location: Crocosaurus Cove

Dress: Smart Casual (please wear shoes suitable for walking around exhibits)

Welcome Reception & Poster ViewingDate: Monday 4 September 2017

Time: 5:30pm - 7:00pm

Location: Exhibition Area (Halls 2/3)

Night at the MoviesDate: Monday 4 September 2017

Time: 7:05pm - 9:45pm

Location: Deckchair Cinema

Dress: Smart Casual (please wear shoes suitable for walking)

ANZSN ASM Sunset Gala DinnerDate: Tuesday 5 September 2017

Time: 7:00pm until Late

Location: DCC Forecourt

Dress: Smart Casual

Entertainment: B2M Acoustic


23

The following rooms can be divided:

Auditorium:into two equal spaces

Halls 1 – 4: into three spaces

Meeting Rooms:into two or four spaces

Waterfront Rooms:into three spaces

Operable walls

Cafe/Bar

Accessible Toilets

Baby Change

Pay Phone

Toilets

Stairs

Escalators

Lift

Conco

urse

Foyer

Foyer

Foyer

Hall 4

Hall 3

Hall 2

Hall 1

Door 2

Auditorium 2

Cafe/Bar

Auditorium 1

Auditorium 2

Auditorium 1

1

34

MeetingRooms

RegistrationDesk

OrganisersO�ce

Porte Cochere

Concourse

Load

ing

Dock

Acces

s to

unde

rgro

und

car p

ark

Roller Door

Rear car park

DarwinHarbour

Door 4

Door 5

Door 6 Door 7

CentreAdministration

LEVEL 1

GROUND LEVEL

LEVEL 2

2

2

3

1

WaterfrontRooms

DARWIN CONVENTION CENTRE FLOOR PLANS

VENUE FLOORPLAN

BREAKOUTS

PLENARY

PLENARY

REGISTRATION

EXHIBITION & CATERING

SPEAKERS PREPARATION ROOM


Nephrology and Transplantation Update Course Waterfront 2, Darwin Convention Centre

Infection diseases and the kidneys

SATURDAY 2ND SEPTEMBER 2017 – DAY 10730 Update Course Registration Concourse,

Ground Level, DCC

Theme 1: Infection disease & the kidneys Chair: Paul Lawton

0800-0830 INFECTION RELATED GLOMERULONEPHRITIS

Asanga Abeyaratne

0830-0900 DIAGNOSIS, TREATMENT AND PREVENTION OF CATHETER RELATED BLOODSTREAM INFECTIONS

Charmaine Lok

0990-0930 MALARIA, DENGUE AND THE KIDNEYS

Basu Gopal*

0930-1000 CMV INFECTION: WHAT IS HOT? WHAT IS NEW?

Camille Kotton

1000-1030 Morning Tea Foyer, Level 2

Theme 2: Renal Replacement Therapy Chair: Muh Geot Wong

1030-1100 CAN WE PREDICT THE UNPREDICTABLE AFTER VASCULAR ACCESS CREATION?

Kevan Polkinghorne

1100-1300 UPDATE IN PERITONEAL DIALYSIS

Matthew Jose

1130-1200 ENVIRONMENTAL IMPACT OF RENAL CARE

Katherine Barraclough

1200-1300 Lunch Foyer, Level 2

Theme 3: Glomerular disease Chair: Katherine Barraclough

PRE ASM COURSES

* APSN SPEAKER


PR

E ASM

CO

UR

SES

1300-1330 UPDATE IN TREATMENTS FOR SYSTEMIC AMYLOIDOSIS

Laura Dember

1330-1400 UPDATE IN ANCA VASCULITIS

Robert MacGinley

1400-1430 UPDATE IN THEARPIES FOR IGA NEPHROPATHY

Muh Geot Wong

1430-1500 UPDATE IN THERAPIES FOR DIABETIC NEPHROPATHY

Carol Pollock

1500-1530 Afternoon Tea Foyer, Level 2

Theme 4: End stage kidney disease Chair: William Majoni

1530-1600 MANAGING VIRAL HEPATITIS IN CKD AND ESKD

Jane Davies

1600-1630 FGF23-AND KLOTHO HOW MUCH SHOULD YOU KNOW?

Nigel Toussaint

1630-1700 WHAT SHOULD BE ON THE PLATE? FOODS FOR ADVANCED CKD

Maria Chan

1830 till late

Nephrology and Transplantation Update Course Dinner Crocosaurus CoveCrocosaurus Cove, located in the heart of Darwin city, allows visitors a unique, up close and personal view of Australia’s iconic Saltwater Crocodiles.Bringing together some of the largest Saltwater Crocodiles in Australia & boasting the World’s largest display of Australian reptiles, Crocosaurus Cove is a must see attraction when visiting Darwin and the Top End.


Nephrology and Transplantation Update Course Waterfront 2, Darwin Convention Centre

SUNDAY 3RD SEPTEMBER 2017 – DAY 20730 Update Course Registration Waterfront 2 Foyer, Darwin

Convention Centre

Theme 5: Transplantation – recipient Chair: Angela Webster

0800-0830 IMMUNODIAGNOSTICS FOR TB, CMV, AND “NET STATE OF IMMUNOSUPPRESSION” IN TRANSPLANT RECIPIENTS

Camille Kotton

0830-0900 HOW TO INTERPRET DONOR SPECIFIC ANTIBODY (DSA)- FOR NON TRANSPLANT PHYSICIAN

Kate Wyburn

0900-0930 BACTERIAL AND FUNGAL INFECTIONS IN THE IMMUNOSUPPRESSED PATIENT -CASE STUDY DISCUSSION

Catherine Marshall

Theme 6: Transplantation – donor Chair: Angela Webster

0930-1000 RISK IN KIDNEY DONATION: HOW MUCH IS TOO MUCH?

Helen Pilmore

1000-1030 Morning Tea Foyer, Level 2

Theme 6: Transplantation – donor Chair: Frank Ierino

1030-1100 CANCER AND DONOR ASSESSMENT

Angela Webster

1100-1130 THE KIDNEY DONOR RISK INDEX (KDRI): A CASE BASED DISCUSSION

Kate Wyburn

Theme 7: Chronic kidney disease Chair: Frank Ierino

1100-1130 URIC ACID AND CKD

Sunil Badve

1130-1200 UPDATE IN ONCONEPHROLOGY

Motoko Yanagita*

1200-1300 Lunch Foyer, Level 2

* APSN SPEAKER


PR

E ASM

CO

UR

SES

1200-1300 ATC INFORMATION SESSION | WATERFRONT 2

Vincent Lee and Natasha Rogers

Theme 7: Chronic kidney disease Chair: Muh Geot Wong

1300-1330 COGNITIVE FUNCTION AND CKD

John Death

1330-1400 SYNDROMIC CKD

Peter Trnka

Theme 8: Research Chair: Muh Geot Wong

1400-1430 EPIGENETIC AND CKD

Masaomi Nangaku*

1430-1500 DATA LINKAGE- WHERE TO START?

Sradha Kotwal

1500-1530 Afternoon Tea Foyer, Level 2

Theme 8: Research Chair: Andrew Mallett

1530-1600 CARDIO METABOLIC RISK AND CKD IN ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLE

Jaquelyne Hughes

Theme 9: Pregnancy Chair: Andrew Mallett

1600-1630 MANAGEMENT OF BP IN PREGNANCY

Vincent Lee

1630-1700 PRE-EXISTING CHRONIC KIDNEY DISEASE AND PREGNANCY

Shilpa Jesudason

1700 Course concludes

* APSN SPEAKER


Renal Dietitians Update Day Program Darwin Convention Centre Meeting Room 2

SUNDAY 3RD SEPTEMBER 20170800 Welcome to Country

0815 Update from DAA Renal IG ChairpersonKaren Salamon, APD

0830 Group activityWHAT IS GOOD EDUCATION?

0900 SHARING EXPERIENCES WORKING WITH MAORI AND PACIFIC ISLANDER POPULATIONS

Jennifer Robb

0930 INDIGENOUS HEALTH – NORTHERN TERRITORY CONTEXT AND PATIENT JOURNEY

NT Dietitians

1000 Morning Tea Foyer, Level 2

1030 Food security and access issues in AustraliaSUCCESSES OF WORKING WITH THE FOOD INDUSTRY IN REMOVING SALT FROM THE FOOD SUPPLY

Associate Professor Julie Brimblecombe

1115 BODY COMPOSITION DIFFERENCES IN ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLE

Dr Jacqui Hughes

1200 Lunch Foyer, Level 2

1300 HEALTH LITERACY – WHAT IS IT AND WHY IS IT IMPORTANT?

Associate Professor Kerry TaylorThe Health Literacy session is designed to be interactive. Participants are encouraged to bring along their educational resources for discussion amongst the group

1330 THE COGNITIVE IMPACTS ON CKD

Associate Professor Angela Webster

PRE ASM COURSES


PR

E ASM

CO

UR

SES

1400 WHAT IS THE LATEST EVIDENCE AND RESEARCH TELLING US ABOUT WHAT PEOPLE UNDERSTAND OF NUTRITIONAL MESSAGES

Ms Kelly Lambert

1500 Afternoon Tea Foyer, Level 2

1530 Panel DiscussionThe Health Literacy session is designed to be interactive. Participants are encouraged to bring along their educational resources for discussion amongst the group

1615 Wrap up for the day

1630 Day concludes


SUNDAY 3RD SEPTEMBER 2017 (PRE-ASM)0800-1700 Council Meeting | Meeting Room 4, Ground Level, DCC

1200-1400 CPAC Meeting | Meeting Room 3, Ground Level, DCC

1430-1630 LOC Meeting for WCN 2019 | Meeting Room 1, Ground Level, DCC

1600-1800 RAC Meeting | Meeting Room 3, Ground Level, DCC

1800-2000 PKD Public Seminar | Meeting Room 2, Ground Level, DCC

1900 President’s Dinner (by invitation only) | Char Restaurant

MONDAY 4TH SEPTEMBER 2017 – ANZSN ASM 20170700 Registration Desk Open Concourse,

Ground Level, DCC

0700 Speakers Preparation Room Meeting Room 4, Ground Level, DCC

0700-0815 Nephrology Editorial Board Meeting Meeting Room 3, Ground Level, DCC

0700-0800 AKTN PISCES TSC Meeting Foyer, Level 2 Fo Meeting Room 1, Ground Level, DCC

Plenary 1 Auditorium 2

Chairs: Carmel Hawley & Jonathan Craig

0800-0815 Welcome to Country – Indigenous RepresentativeWelcome to Delegates – Dr Paul Lawton, ASM Co-Chair

0815-0900 Plenary Speaker: Laura DemberPRAGMATIC CLINICAL TRIALS: AN APPEALING ALTERNATIVE

0900-0930 TJ Neale Award

0930-1000 Jacquot Award Past RecipientsNatasha Rogers & Katherine Barraclough

PROGRAM


PR

OG

RA

M

1000-1030 Morning Tea Exhibition Area, Hall 2-3, Ground Level, DCC

Young Investigator Award Prize Orals Auditorium 2

Chair: Carol Pollock

1030-1045 OVERALL AND SITE SPECIFIC CANCER MORTALITY IN PATIENTS ON RENAL REPLACEMENT THERAPY

Eric Au

1045-1100 JNK1 BUT NOT JNK2 PROMOTES RENAL ISCHAEMIA/REPERFUSION INJURY

Keren Grynberg

1100-1115 IDENTIFYING A CORE VASCULAR ACCESS OUTCOME FOR ALL TRIALS IN HAEMODIALYSIS: AN INTERNATIONAL SURVEY WITH PATIENTS AND HEALTH PROFESSIONALS

Andrea Viecelli

1115-1130 BLOCKADE OF KCA3.1 WITH TRAM34 ATTENUATES ESTABLISHED DIABETIC NEPHROPATHY

Chunling Huang

1130-1145 DIETARY N-3 AND N-6 POLYUNSATURATED FATTY ACID INTAKE AND RISK OF MORTALITY IN PEOPLE ON HEMODIALYSIS: THE DIET-HD MULTINATIONAL COHORT STUDY

Valeria Saglimbene

1145-1200 NLRP3 INFLAMMASOME BLOCKADE ATTENUATES DISEASE IN ANTI-MPO GLOMERULONEPHRITIS

Holly Hutton

1200-1215 IDENTIFYING IMPORTANT OUTCOMES FOR CHILDREN WITH CHRONIC KIDNEY DISEASE AND THEIR CAREGIVERS: FOCUS GROUPS WITH NOMINAL GROUP TECHNIQUE

Camilla Hanson

1215-1230 BLOCKADE OF RIPK3 ATTENUATES FOLIC ACID-INDUCED KIDENY FIBROSIS OF C57BL/6 MOUSE

Ying Shi

1230-1330 Lunch Exhibition Area, Hall 2-3, Ground Level, DCC

Amgen Australia Pty Ltd, ABN 31 051 057 438, Level 7, 123 Epping Road, North Ryde, NSW 2113. AU-0841 August 2017. NEPH6828 BBK08/17.

INNOVATION

IN EVERYTHING WE DO

RELIABILITY

THAT PERSISTS

QUALITY

FROM THE START


PR

OG

RA

M

1330-1500 Mini Orals Session 5 minute presentation, 2 minute questions

Mini Orals Waterfront 1

General Nephrology – Epidemiology

Mini OralsWaterfront 2

Transplantation


Haemodialysis and Peritoneal Dialysis

Chairs: Germaine Wong & Anna Francis

Chairs: Wai Lim & Doreen Wang

Chairs: Peter Kerr & Murray Leikis

THE ROLE OF TUMOUR NECROSIS FACTOR RECEPTOR 1 (TNFR1) IN THE PROGRESSION OF KIDNEY DISEASE IN INDIGENOUS AUSTRALIANS: THE EGFR FOLLOW-UP STUDY

Federica Barzi

THE BENEFITS AND COSTS OF SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION COMPARED WITH DIALYSIS AND KIDNEY-ALONE TRANSPLANTATION IN PATIENTS WITH TYPE 1 DIABETES MELLITUS AND END-STAGE KIDNEY DISEASE

Rashmi Shingde

EXERCISE WITH BLOOD FLOW RESTRICTION DURING DIALYISIS SAFE AND TOLERABLE

Catherine A Brumby

AUTONOMOUS DECISION-MAKING IN ADULTS WITH CHRONIC KIDNEY DISEASE

Charlotte McKercher

PRE-ECLAMPSIA IN PREGNANCIES AFTER KIDNEY TRANSPLANTATION (KT): DETERMINANTS AND IMPACT ON PREGNANCY AND GRAFT OUTCOMES

Shilpanjali Jesudason

ENDOVASCULAR EVENTS, HEART FAILURE AND SURVIVAL IN DIALYSIS PATIENTS

Brendan Smyth

IMPACT OF PRIVATE HEALTH INSURANCE ON DIALYSIS OUTCOMES – A COHORT STUDY

Arunan Sriravindrarajah, Sradha Kotwal

IMPACT OF RISK-BASED, DECEASED-DONOR KIDNEY ALLOCATION ALGORITHM ON GRAFT AND PATIENT SURVIVAL

Vaishnavi Calisa

THE UPTAKE OF HAEMODIAFILTRATION IN AUSTRALIA AND NEW ZEALAND: AN ANZDATA REGISTRY STUDY

Emily See

RESEARCH OUTPUTS REPORTING INDIGENOUS HEALTH OUTCOMES IN THE AUSTRALIA AND NEW ZEALAND DIALYSIS AND TRANSPLANT REGISTRY (ANZDATA): SYSTEMATIC REVIEW

Suetonia Palmer

HUMAN LEUKOCYE ANTIGEN (HLA)-DQA AND DQB EPLET MISMATCHES AND DE NOVO DONOR-SPECIFIC ANTI-HLA-DQ ANTIBODY

Wai Lim

PREVALENCE AND PATTERNS OF COGNITIVE IMPAIRMENT IN ADULTS ON HAEMODIALYSIS: THE COGNITIVE-HD STUDY

Anita Van Zwieten


PREVALENCE AND CORRELATES OF DEPRESSION IN ADULTS WITH CHRONIC KIDNEY DISEASE

Charlotte Mckercher

AN OBSERVATIONAL STUDY OF INSULIN RESISTANCE IN PATIENTS WITH POST TRANSPLANT DIABETES MELLITUS ON DPP-4 INHIBITOR THERAPY AND OTHER AGENTS

Srivathsan Thiruvengadam

FRUIT INTAKE AND CARDIOVASCULAR AND ALL-CAUSE MORTALITY IN ADULTS ON HEMODIALYSIS: THE DIET-HD MULTINATIONAL COHORT STUDY

Valeria Saglimbene

SEX MATTERS: GENDER-RELATED DIFFERENCE IN RENAL REPLACEMENT THERAPY (RRT) INCIDENCE RATES

Stephen Mcdonald

INCIDENCE, TYPES AND PREDICTORS OF ACUTE REJECTION IN INDIGENOUS KIDNEY TRANSPLANT RECIPIENTS IN WESTERN AUSTRALIA

Prue Howson

CHANGE OF SUBJECTIVE GLOBAL ASSESSMENT (SGA) SCORE IS ASSOCIATED WITH A CHANGE IN SERUM ALBUMIN AND HAND GRIP STRENGTH

Maria Chan

ABSOLUTE RISK AND RISK FACTORS FOR STROKE MORTALITY IN PATIENTS WITH END STAGE KIDNEY DISEASE (ESKD): RETROSPECTIVE POPULATION-BASED COHORT USING DATA LINKAGE

Nicole De La Mata

WHY DON’T ALL LIVING KIDNEY DONOR CANDIDATES PROCEED TO DONATION?

Ellie Cash

IMPROVING THE SAFETY OF HAEMODIALYSIS BY OPTIMISING ANTICOAGULATION (ISHAN): A PILOT STUDY

Matthew Jose

ASSOCIATION OF DIALYSIS ATTENDANCE WITH KIDNEY TRANSPLANT OUTCOMES IN NORTHERN TERRITORY (NT) BASED KIDNEY TRANSPLANT RECIPIENTS

Namrata Khanal

A SYSTEMATIC REVIEW OF INCIDENCE AND PREVALENCE OF HIV IN INCREASED RISK GROUPS IN AUSTRALIA TO AID DECISION-MAKING IN INCREASED RISK ORGAN DONOR REFERRALS

Karen Waller

WHICH BLOOD PRESSURE MEASUREMENTS SHOULD DRIVE THERAPY IN A TRIAL OF INTENSIVE VERSUS USUAL TREATMENT OF HYPERTENSION IN HEMODIALYSIS PATIENTS?

Antonia Harford

PROGRESSION OF KIDNEY DISEASE IN A COHORT OF CHRONIC KIDNEY DISEASE (CKD) PATIENTS

Wendy Hoy

ASSOCIATION BETWEEN EPLET HLA-MISMATCHES, DE NOVO DSA PRODUCTION AND RISK OF REJECTION IN PAEDIATRIC KIDNEY TRANSPLANT RECIPIENTS

Ankit Sharma

RAPID FLOW CYTOMETRIC IDENTIFICATION AND ANALYSIS OF STAPHYLOCOCCUS SPP. FROM PERITONEAL DIALYSATE

Aron Chakera


PR

OG

RA

M

NEPHROLOGISTS’ PERSPECTIVES ON CANCER SCREENING IN PATIENTS WITH CHRONIC KIDNEY DISEASE

Laura J James

LONG-TERM OUTCOME OF OVERSEAS KIDNEY TRANSPLANT RECIPIENTS – A REGISTRY ANALYSIS

Wai Lim

OBESITY IS NOT ASSOCIATED WITH INCREASED MORTALITY IN AUSTRALIA AND NEW ZEALAND PERITONEAL DIALYSIS PATIENTsSuresh Murthy

COMPARISON OF FACT AND CAUSE OF DEATH BETWEEN ANZDATA AND THE NATIONAL DEATH INDEX

Matthew Sypek

LONG-TERM GRAFT AND PATIENT OUTCOMES OF KIDNEY TRANSPLANT RECIPIENTS WITH INCIDENT CANCER – A POPULATION COHORT STUDY

Wai Lim

EARLY MESOTHELIAL CELL RESPONSES TO STAPHYLOCOCCUS EPIDERMIDIS INFECTION

Aron Chakera

ASSOCIATION OF DIALYSIS ATTENDANCE WITH WAITLISTING OF NORTHERN TERRITORY (NT) BASED END STAGE KIDNEY DISEASE (ESKD) PATIENTS

Namrata Khanal

ESTABLISHMENT OF A “RISK CALCULATOR” FOR KIDNEY TRANSPLANT RECIPIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)

David Goodman

PRE-STERNAL PERITONEAL DIALYSIS CATHETERS: 14-YEAR EXPERIENCE IN A SINGLE CENTRE

LaiWan Chan

1500-1530 Afternoon Tea Exhibition Area, Hall 2-3, Ground Level, DCC

1530-1700 Seminar & KHA Awards

Seminar 1 : Basic Science Auditorium 2

Translational PKD Symposium

KHA Award Orals Waterfront 2

Chairs: Jackie Phillips & Gopala Rangan

Chair: Angela Webster

1530-1550 BASIC SCIENCE: RENAL PRIMARY CILIA AS REGULATORS OF EPITHELIAL REPAIR AND RELEVANCE TO PKD

Sharon Ricardo

DIFFICULT CONVERSATIONS: AUSTRALIAN INDIGENOUS PATIENTS’ VIEWS ON KIDNEY TRANSPLANTATION

Alan Cass


1550-1610 EPIGENETICS: TISSUE SPECIFIC TARGETING OF THERAPIES FOR PKD

Cherie Stayner

CHRONIC KIDNEY DISEASE IN AUSTRALIAN GENERAL PRACTICE: ITS PREVALENCE, AND ASSOCIATED PATIENT CHARACTERISTICS AND COMORBIDITIES

Matthew Jose

1610-1630 PRECLINICAL STUDIES: PKD, HEART DISEASE AND THE AUTONOMIC NERVOUS SYSTEM

Cara Hildreth

ADVERSE PREGNANCY OUTCOMES IN WOMEN WITH KIDNEY DISORDERS – A POPULATION STUDY OF >400,000 PREGNANCIES IN SOUTH AUSTRALIA (SA): 1990-2012

Alyssa Fitzpatrick

1630-1650 TREATMENT OUTCOMES: STANDARDISED OUTCOMES IN NEPHROLOGY

Allison Tong

EFFECTS OF FISH OIL SUPPLEMENTATION AND ASPIRIN USE ON ARTERIOVENOUS FISTULA PATENCY, NEED FOR INTERVENTIONS AND DIALYSIS SUITABILITY IN PATIENTS REQUIRING HAEMODIALYSIS – POST HOC ANALYSIS OF THE FAVOURED STUDY

Andrea Viecelli

1650-1700 PANEL THE IMPACT OF CHRONIC KIDNEY DISEASE (CKD) ON THE QUALITY OF LIFE OF CHILDREN AND ADOLESCENTS

Anna Francis

ASSOCIATION BETWEEN DURATION OF DELAYED GRAFT FUNCTION AND ALLOGRAFT OUTCOME AFTER KIDNEY TRANSPLANTATION

Wai Lim

1700-1730 ANZSN Annual General Meeting Waterfront 1

1730-1900 Welcome Reception & Poster Viewing Exhibition Area

1900 Walk to Deckchair (5 mins), follow the committee!

1905-2145 Night at the Movies Deckchair Cinema


PR

OG

RA

M

TUESDAY 5TH SEPTEMBER 2017- ANZSN ASM 20170730 Registration Desk Open Concourse,

Ground Level, DCC

0700 Speakers Preparation Room Meeting Room 4 Ground Level, DCC

0700-0745 Australasian Kidney Trials Network Meeting Room 1-2, Breakfast Meeting (fully booked) Ground Level, DCC

Plenary 2 Auditorium 2

Chair: Nikki Isbel & Robyn Langham

0800-0900 Plenary Speaker: Camille KottonPRETRANSPLANT EVALUATION FROM AN INFECTIOUS DISEASE PERSPECTIVE: SCREENING, VACCINES, AND ENHANCING SAFETY

0900-0930 Equity and diversity in ANZSNAngela Webster

WIRELESSNETWORK NAME: ANZSN ASM

PASSWORD: anzsnasm

MONTHLY EFFICACY

1#

# Maintaining target Hb levels in CKD patients with anaemia, with monthly administration.

methoxy polyethylene glycol-epoetin beta

Please review the complete Product Information before prescribing, available at www.roche-australia.com/productinfo/mircera or phone 1800 233 950.

MINIMUM PRODUCT INFORMATION MIRCERA® (methoxy polyethylene glycol-epoetin beta) Indications: Treatment of anaemia associated with chronic kidney disease (CKD). Dosage & Administration: Administered by IV or SC injection. Use the lowest dose of MIRCERA that will gradually increase the Hb concentration. The recommended Hb target is 100 - 120 g/L. Patients not currently treated with an ESA: Not on dialysis - recommended starting dose is 1.2 µg/kg body weight monthly as a single SC injection or alternatively 0.6 µg/kg body weight, once every 2 weeks (IV or SC). On dialysis - recommended starting dose is 0.6 µg/kg body weight, once every 2 weeks. Patients currently treated with an ESA: recommended starting dose (monthly or fortnightly) is based on the previous weekly ESA dose as per below;

Previous Darbepoetin alfa dose (µg/wk) Previous Epoetin dose (IU/wk) MIRCERA dose* (µg/month)

< 4040 – 80

> 80

< 80008000 – 16000

> 16000

120200360

*fortnightly dose is approx half the monthly doseContraindications and Precautions: Contraindicated in patients with uncontrolled hypertension or known hypersensitivity to the active substance or any excipient. Should not be used in patients < 18 years. Cardiovascular and thrombotic events; monitor and control BP; hypertensive encephalopathy seizures; pure red cell aplasia (PRCA); use with caution in patients with epilepsy, haemoglobinopathies or platelet levels > 500 x 109/L; monitor iron status; Vitamin B, folic acid or iron deficiencies, chronic blood loss, bone marrow fibrosis, haemolysis and severe aluminium overload may compromise the effectiveness of therapy. Adverse Effects: Hypertension; diarrhoea; nasopharyngitis; upper respiratory tract infection; headache; procedural hypotension; muscle spasms; back pain; cough; fluid overload. Post-marketing: PRCA. Please review the full Product Information before prescribing, available on request from Roche Products Pty Limited (www.roche-australia.com/productinfo/mircera). Reference: 1. MIRCERA Approved Product Information. Available at: www.roche-australia.com/productinfo/mircera. Further information is available from Roche Products Pty Limited, ABN 70 000 132 865, Level 8, 30-34 Hickson Road, Sydney NSW 2000. Medical Information: 1800 233 950. ®Registered Trademark. EMVMIR0180 MN37561530 PreparedAug17.

PBS Information: This product is listed on the PBS as a Section 100 item. Refer to PBS Schedule for full authority information.


PR

OG

RA

M

0930-1030 Seminar 2 Basic Science & Mini Orals Session 2

Seminar 2: Basic Science; Diabetes

Waterfront 1

Mini Orals Waterfront 2Experimental

Immunology and Developmental

Biology

Mini OralsWaterfront 3Paediatric and

Pregnancy Associated

Chairs: Josephine Forbes & Melinda Coughlan

Helen Healy & Aaron Chakera

Peter Trnka & Shilpa Jesudason

0930-0950 THE ROLE OF OXIDATIVE STRESS IN DIABETIC NEPHROPATHY

Karin Jandeleit-Dahm

THE IMPACT OF INTRAUTERINE INFLAMMATION ON FETAL RENAL DEVELOPMENT

Megan Sutherland

SCOPE AND CONSISTENCY OF OUTCOMES REPORTED IN RANDOMISED TRIALS CONDUCTED IN CHILDREN WITH CHRONIC KIDNEY DISEASE

Camilla Hanson

RENAL EXPRESSION OF TOLL-LIKE RECEPTORS IN PATIENTS WITH CRESCENTIC GLOMERULONEPHRITIS

Kim Maree O’Sullivan

MITOCHONDRIAL DYSFUNCTION DEFINES A POPULATION OF YOUNG PEOPLE WITH TYPE 1 DIABETES AT RISK OF KIDNEY DISEASE

Nikki Isbel

0950-1010 METABOLIC MEMORY AND HYPOXIC MEMORY: EPIGENETICS IN DIABETIC NEPHROPATHY

Masaomi Nangaku*

INTERLEUKIN (IL)-17 PRODUCTION BY TUBULOINTERSTITIAL HUMAN GAMMA-DELTA T CELLS IN RENAL FIBROSIS AND CHRONIC KIDNEY DISEASE

Andrew Kassianos

NEUROCOGNITIVE AND EDUCATIONAL OUTCOMES IN CHILDREN AND ADOLESCENTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Kerry Chen


DEVELOPMENT OF MONOCLONAL ANTIBODIES FOR USE IN A NEW MOUSE MODEL OF VASCULITIS

Holly Hutton

PRE-ECLAMPSIA IS ASSOCIATED WITH CHANGES IN THE ABUNDANCE AND PHOSPHORYLATION OF SODIUM TRANSPORTERS IN URINARY EXOSOMES

Peter Mount

1010-1030 NOVEL THERAPIES BASED ON THE PATHOPHYSIOLOGY OF DIABETIC NEPHROPATHY

Carol Pollock

FLT3 INHIBITOR ATTENUATES RENAL INJURY IN ADRIAMYCIN NEPHROPATHY BY SUPPRESSING CD103+ DC-MEDIATED T CELL ACTIVATION

Padmashree Rao

EFFECT OF PLACENTAL GROWTH FACTOR ON TROPHOBLAST INTEGRATION INTO ENDOTHELIAL CELL NETWORKS

Katrina Chau

LOCALLY SECRETED ICOS-IG PROLONGS SURVIVAL OF XENOGRAFTS AND ALLOGRAFTS

Francesco Ierino

SOCIOECONOMIC STATUS AND HEALTH IN CHILDREN AND ADOLESCENTS WITH CHRONIC KIDNEY DISEASE – THE KIDS WITH CKD STUDY (KCAD)

Madeleine Didsbury

A PHASE 1 STUDY OF MESENCHYMAL STROMAL CELLS AND ISCHAEMIA REPERFUSION INJURY IN DECEASED DONOR RENAL TRANSPLANTATION

Ashley Irish

INTRAUTERINE GROWTH RESTRICTION: ADVERSE EFFECTS ON RENAL GROWTH AND FUNCTION IN PRETERM INFANTS

Megan Sutherland

EARLY POSTNATAL IMPAIRMENT OF RENAL FUNCTION IN INDIGENOUS INFANTS BORN PRETERM

Megan Sutherland


PR

OG

RA

M

1030-1100 Morning Tea Exhibition Area, Hall 2-3, Ground Level, DCCRenal Scientists Meeting Meeting Room 3

Ground Level, DCC

1100-1200 Trainee Prize & Mini Orals Session 3

Shaun Summers Clinical Trainee Prize Session

Waterfront 1


Haemodialysis General and Access / Peritoneal Dialysis

Mini OralsWaterfront 3Experimental

Tubulointersitital / Acute Kidney Injury

Chair: Francesco Ierino Chairs: Robert MacGinley & Tracey

Putt

Chairs: Wendy Hoy & Jay Chandra

UTILITY OF KIDNEY BIOPSY IN PATIENTS WITH SIGNIFICANT PROTEINURIA IN THE NON-NEPHROTIC RANGE

Richard Germann

THE PERSPECTIVES OF HEALTHCARE PROVIDERS ON THE NUTRITIONAL MANAGEMENT OF PATIENTS ON HAEMODIALYSIS: AN INTERVIEW STUDY

Jessica Stevenson

INCREASED FIBROSIS IN ACC KNOCKIN MICE FOLLOWING RENAL INJURY CONFIRMS A PATHOGENIC ROLE FOR REDUCED FATTY ACID OXIDATION

Mardiana Lee

ATYPICAL HAEMOLYTIC URAEMIC SYNDROME IN AUSTRALIA: REAL-WORLD CHALLENGES AND LESSONS FROM THE THROMBOTIC MICROANGIOPATHY REGISTRY

Kate Robson

IDENTIFYING THE CRITICAL DIMENSIONS OF FATIGUE FOR A CORE OUTCOME MEASURE FOR TRIALS IN HAEMODIALYSIS: AN INTERNATIONAL SURVEY

Angela Ju

EPIGENETIC MODIFICATIONS TO H3K9 IN RENAL TUBULOINTERSTITIAL CELLS AFTER UNILATERAL URETERIC OBSTRUCTION AND TGF-BETA1 STIMULATION

Tim Hewitson

BIOCHEMICAL COMPARISON OF 8-HOUR HAEMODIALYSIS AND 4-HOUR HAEMODIAFILTRATION, AND TWO DIALYSIS MEMBRANES

Shi Zhou Choo

REPEATED SUBCLINICAL BLOOD-PRESSURE VOLATILITY DEMONSTRATED BY CONTINUOUS MONITORING DURING CONVENTIONAL OUTPATIENT HAEMODIALYSIS

Jacqui Evans, Scott Wilson

ROLE OF NADPH-OXIDASE NOX5 IN HUMAN DIABETIC NEPHROPATHY

Jay Jha


COMPARING PATIENT SURVIVAL ON HAEMODIAFILTRATION AND HAEMODIALYSIS: AN ANZDATA REGISTRY STUDY

Emily See

REPORT OF THE STANDARDISED OUTCOMES IN NEPHROLOGY-HAEMODIALYSIS (SONG-HD) CONSENSUS WORKSHOP ON ESTABLISHING A CORE OUTCOME MEASURE FOR VASCULAR ACCESS IN HAEMODIALYSIS

Andrea Viecelli

CHRONIC FETAL HYPOXIA LEADS TO LONG-TERM PROXIMAL TUBULE INJURY IN THE SHEEP KIDNEY

Megan Sutherland

THE EFFECT OF LARGE BODY WEIGHTS ON PD OUTCOMES

Mahmoud Amer

VASCULAR ACCESS OUTCOMES REPORTED IN RANDOMISED TRIALS CONDUCTED IN PATIENTS REQUIRING HAEMODIALYSIS: A SYSTEMATIC REVIEW

Andrea Viecelli

MODULATION OF UPREGULATED TRANSCRIPTIONAL SIGNALING PATHWAYS IN RODENT DIABETIC NEPHROPATHY AFTER TREATMENT WITH A NOVEL ANTI-FIBROTIC AGENT FT011: CORRELATES WITH HUMAN DIABETIC KIDNEY DISEASE

Robyn Langham

ASSOCIATION BETWEEN CAUSES OF PERITONEAL DIALYSIS TECHNIQUE FAILURE AND ALL-CAUSE MORTALITY

Jenny HC Chen

OUTCOMES OF SUBCUTANEOUSLY BURIED PERITONEAL DIALYSIS CATHETERS BETWEEN 2006 AND 2014 AT ROYAL DARWIN HOSPITAL

Thwe Thwe Soe

RENAL TUBULAR EPITHELIAL CELL ISOMETRIC VACUOLATION ASSOCIATED WITH SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITOR USE: A CASE REPORT

Beata Zahorowska

FATHERHOOD WHILE RECEIVING DIALYSIS AND AFTER KIDNEY TRANSPLANTATION: ANALYSIS OF THE AUSTRALIAN AND NEW ZEALAND DIALYSIS AND TRANSPLANTATION (ANZDATA) REGISTRY, 1970-2014

Alyssa Fitzpatrick

ASEPTIC TECHNIQUE MAINTAINS STERILITY OF ANTIBIOTIC-LOADED PERITONEAL DIALYSIS FLUID

Louis Huang

ACTIVATED CD47 PROMOTES ACUTE KIDNEY INJURY BY LIMITING AUTOPHAGY

Natasha Rogers


PR

OG

RA

M

IMPACT OF BELATACEPT CONVERSION ON KIDNEY TRANSPLANT FUNCTION, HISTOLOGY AND GENE EXPRESSION

Pooja Sanghi

PD BUDDY: USING SMARTPHONE TECHNOLOGY TO IMPROVE PATIENT CARE

Marnie Budd, Robyn Rogers

RENAL SAFETY OF A SHORT COURSE OF GENTAMICIN IN ELDERLY PATIENTS (THE REGENT STUDY)

Christopher Sia

1205-1305 ANZDATA & Mini Orals Session 4

ANZDATAWaterfront 1

Mini Orals Waterfront 2Experimental

Tubulonterstitial / Acute Kidney Injury


Cardiovascular / Hypertension / CKD-Mineral Bone Disease/

Anaemia/Adequacy

Chair: Matthew Jose Chairs: Andrew Mallett &

Poh Yi Gan

Chairs: Suetonia Palmer & Murali Gangadharan

Komala

ANZDATA overviewMatthew Jose

RIPK1 INHIBITION ALLEVIATES RENAL FIBROGENESIS

Ying Shi

BLOOD PRESSURE AND RESPIRATORY SYMPATHETIC MODULATION IN AN ANIMAL MODEL OF CHRONIC KIDNEY DISEASE AFTER BILATERAL CAROTID SINUS DENERVATION

Manash Saha

Patient Reported Outcome MeasuresAndy Salmon

ANALYSIS OF APICAL AND BASOLATERAL SECRETED EXOSOMES FROM HUMAN PROXIMAL TUBULE EPITHELIAL CELLS (PTEC) UNDER NORMAL AND DISEASED CONDITIONS

Xiangju Wang

LIPID-LOWERING THERAPY AMONG CKD PATIENTS IN AUSTRALIAN GENERAL PRACTICE

Masuma Khanam

TRANSIENT INCREASE IN WATER INTAKE IS SUFFICIENT TO REDUCE LONGTERM CARDIORENAL PROGRESSION IN LPK RATS

Priyanka Sagar

A RARE CASE OF GENE CYP11B1 DEFICIENCY CAUSING HYPERALDOSTERONISM

Masnun Kayes

For nearly half a century we have been helping patients with end stage renal disease live fuller, richer and more active lives. We are committed to life and to life-changing outcomes.

Fresenius Medical Care - www.fmc-au.com


PR

OG

RA

M

USING THE GEOMETRIC FRAMEWORK TO EXPLORE THE LONGITUDINAL EFFECTS OF DIETARY MACRONUTRIENT CONSUMPTION ON MARKERS OF KIDNEY AGEING

Josephine Forbes

A NOVEL AND UNIQUE PROTEIN I-BODY AD-114 INHIBITED TGFβ1-INDUCED EXPRESSION OF FIBRONECTIN AND COLLAGEN 4 IN RENAL PROXIMAL TUBULAR CELLS

Qinghua Cao

Transplant wait listing and organ utilisationMatthew Sypek

A NOVEL LONG NON-CODING RNA (LNCRNA) IN DIABETIC KIDNEY DISEASE

Sanela Redzepagic

CHANGES IN BONE AND MINERAL METABOLISM MARKERS AFTER CESSATION OF CINACALCET IN DIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM

Irene Ruderman

ELEVATED SERUM CREATININE AND ACUTE KIDNEY INJURY FOLLOWING RADICAL TUMOUR NEPHRECTOMY

Robert Ellis

DETERIORATION OF CORTICAL BONE MICROARCHITECTURE IN RENAL OSTEODYSTROPHY – UNDER-REPRESENTED IN THE ‘TURNOVER MINERALISATION VOLUME’ (TMV) CLASSIFICATION?

Ashish Sharma

Examination of Centre Effects using the ANZDATA RegistryCarmel Hawley

USING THE KINETIC EGFR FORMULA FOR DETECTING AKI AND ESTIMATING GFR IN THE NON ICU SETTING

Faith See Huiwen

EFFECTIVE SOLUTE CLEARANCE KINETICS ACROSS SEQUENTIAL HIGH-FLUX HAEMODIALYSIS (HD) TREATMENTS BY TIME-SERIES ANALYSIS OF FREQUENTLY SAMPLED EFFLUENT DIALYSATE ALIQUOTS

Ryan Slack, Scott Wilson

β-CATENIN/FOXO PROTECTS AGAINST KIDNEY FIBROSIS

Padmashree Rao

Lunch Exhibition Area, Hall 2-3, Ground Level, DCCKHA-CARI Indigenous Guidelines Meeting Room 3

Ground Level, DCC


1400-1530 Seminar 3 & Basic Science Award

Seminar 3: Clinical ScienceAuditorium 2

Basic Science AwardWaterfront

Chairs: Alan Cass & William Majoni Natasha Rogers

1400-1430 DIALYSIS MODALITIES

Charmaine LokBIOLOGICALS TARGETING CYTOKINES INDUCING CD4+ TH CELL SUBSET DIFFERENTIATION FOR THE TREATMENT OF EXPERIMENTAL ANTI-MPO GN

Poh-Yi Gan

IL-33 EXACERBATES IGA GLOMERULONEPHRITIS IN B CELL ACTIVATING FACTOR (BAFF) TRANSGENIC MICE

Yuan Min Wang

1430-1500 TRAVEL MEDICINE FOR TRANSPLANT PATIENTS (“THE ICING ON THE CAKE”)

Camille Kotton

CYCLOPHILIN INHIBITION PREVENTS SEVERE RENAL ISCHAEMIA/REPERFUSION INJURY

Khai Gene Leong

A PERIPHERALLY ACTING CANNABINOID RECEPTOR 1 ANTAGONIST SUPPRESSES RENAL INTERSTITIAL FIBROSIS

David Nikolic-Paterson

1500-1530 AGING AND THE KIDNEYS

Motoko Yanagita*

DOMINANT HLA-MEDIATED PROTECTION FROM THE RISK OF AUTOIMMUNE RENAL DISEASE IS CONFERRED BY ANTIGEN-SPECIFIC REGULATORY CELLS

Joshua Ooi

FOLLISTATIN MODULATES ISCHAEMIA-REPERFUSION-INDUCED RENAL FIBROSIS IN MICE

Doreen Fang

1530-1600 Afternoon Tea Exhibition Area, Hall 2-3, Ground Level, DCC


PR

OG

RA

M

1600-1745 Mini Orals Session 5


Transplantation


General Nephrology


Epidemiology / Health Services

Chairs: Katherine Barraclough & Michael Collins

Chairs: Muh Geot Wong & Andrew McNally

Chairs: Martin Gallagher & Paul Lawton

NOVEL HLA ALLELES AND EPLET MISMACTHES IN INDIGENOUS RENAL TRANSPLANT RECIPIENTS

Ankit Sharma

EFFECTS OF DIMETHYL FUMARATE ON RENAL MACROPHAGE ACCUMULATION AND CYST GROWTH IN EXPERIMENTAL POLYCYSTIC KIDNEY DISEASE

Oliver Oey

ISCHAEMIC HEART DISEASE MORTALITY IN PEOPLE WITH END STAGE KIDNEY DISEASE IN AUSTRALIA AND NEW ZEALAND: A COHORT STUDY FROM 1980 TO 2013

Angela Webster

SPECIFIC DETECTION OF GRAFT DERIVED DNA IN THE PLASMA DURING ANTIBODY MEDIATED REJECTION: DEVELOPMENT OF A NEW DIAGNOSTIC TOOL

John Whitlam

PILOT STUDY: URINARY INDOXYL SULPHATE AS A PREDICTOR OF POSTOPERATIVE KIDNEY FUNCTION FOLLOWING RADICAL TUMOUR NEPHRECTOMY

Robert Ellis

THE HEALTHTRACK STUDY- A RANDOMISED CONTROL TRIAL OF INTERDISCIPLINARY CARE ON WEIGHT LOSS 12 MONTH FOLLOW UP

Maureen Lonergan

INVESTIGATING ANAL NEOPLASIA IN KIDNEY TRANSPLANT RECIPIENTS: A CROSS-SECTIONAL PILOT STUDY

Angela Webster

BOWEL HABITS AND THE ASSOCIATION WITH SERUM P-CRESYL SULFATE IN CKD PATIENTS

Christiane Ramos

MORTALITY OUTCOMES FOR MĀORI AND NON-MĀORI AFTER COMMENCING RENAL REPLACMENT THERAPY IN AOTEAROA/NEW ZEALAND: A KAUPAPA MĀORI APPROACH

Suetonia Palmer

* APSN SPEAKER


THE LIVED EXPERIENCE OF ‘BEING EVALUATED’ FOR ORGAN DONATION: FOCUS GROUPS WITH LIVING KIDNEY DONORS

Camilla Hanson

AN EXTRACTION TOOL FOR CHRONIC KIDNEY DISEASE DATA FROM AUDIT4

Wendy E Hoy

DECISION-MAKING AMONG CALD ADULTS WITH CHRONIC DISEASE: A SYSTEMATIC REVIEW OF BARRIERS, FACILITATORS, AND INTERVENTIONS

Danielle Muscat

COMPARISON OF U.K. AND U.S. KIDNEY DONOR RISK INDICES (KDRIS) IN THE AUSTRALIAN AND NEW ZEALAND POPULATION

Kathryn Dansie

ANTHROPOMETRIC PROFILE IN INDIGENOUS AUSTRALIANS IN THE EGFR STUDY

Camilla Feeney

RENAL SUPPORTIVE CARE: CURRENT EXPERIENCES IN VICTORIA

Kathryn Ducharlet

ANAEMIA IN KIDNEY TRANSPLANT RECIPIENTS IN THE FIRST YEAR

Andy Lim

ENDOTHELIAL GLYCOCALYX DAMAGE IN KIDNEY DISEASE IS REFLECTED BY SERUM BIOMARKERS BUT NOT THE PERFUSED BOUNDARY REGION

Hui Liew

DECISION-MAKING ACROSS THE CKD TRAJECTORY: A QUALITATIVE INTERVIEW STUDY WITH CALD PATIENTS

Danielle Muscat

INCREASED RECRUITMENT OF LYMPHOCYTE SUBSETS IN HUMAN KIDNEY TRANSPLANT REJECTION

Katrina Kildey

WHAT ARE THE INFECTIONS THAT AUSTRALIANS ON RENAL REPLACEMENT THERAPY DIE FROM?

Alison Graver

PATIENT PREFERENCES FOR DIALYSIS MODALITIES: A DISCRETE-CHOICE EXPERIMENT

Rachael Walker

TIME COURSE AND RATES OF REJECTION IN ATSI RENAL TRANSPLANT RECIPIENTS

Ramyasuda Swaminathan

EXPRESSION OF URINARY MICRORNAS AS NOVEL DIAGNOSTIC BIOMARKERS FOR DIABETIC KIDNEY DISEASE

Qinghua Cao

CHRONIC KIDNEY DISEASE (CKD) MONITORING IN AUSTRALIAN GENERAL PRACTICE

Masuma Khanam

END STAGE KIDNEY DISEASE RISK PROFILE IN LIVING KIDNEY DONORS FOR PAEDIATRIC VERSUS ADULT KIDNEY TRANSPLANT RECIPIENTS IN AUSTRALIA AND NEW ZEALAND

Matthew Roberts

PHARMACOKINETICS OF METFORMIN IN SETTING OF CKD

Tracey Putt

THE DIALYSIS MODELS OF CARE PARTNERSHIP: LINKING HOSPITAL ADMINISTRATIVE AND ANZDATA REGISTRY DATA FOR NORTHERN TERRITORY (NT) RENAL REPLACEMENT THERAPY (RRT) RECIPIENTS

Shamsir Ahmed


PR

OG

RA

M

TWENTY YEARS EXPERIENCE OF RENAL TRANSPLANTATION FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM). RISK FACTORS THAT INFLUENCE GRAFT AND PATIENT SURVIVAL

David Goodman

PREVALENCE OF SARCOPENIA IN PATIENTS ON DIALYSIS AND THE CORRELATION BETWEEN MUSCLE STRENGTH, MUSCLE MASS AND FUNCTION AS DETERMINANTS OF SARCOPENIA IN THE DIALYSIS POPULATION

Muralikrishna Gangadharan Komala

BLOOD PRESSURE MANAGEMENT IN HYPERTENSIVE PATIENTS WITH NON-DIALYSIS CHRONIC KIDNEY DISEASE IN QUEENSLAND, AUSTRALIA

Jenny Zhang

TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY IN NON-RENAL SOLID ORGAN TRANSPLANT PATIENTS: A CASE SERIES

Brian Doucet

TREATMENT PARADIGM IN A YOUNG MALE WITH GERM CELL TUMOUR WITH WORSENING IGA NEPHROPATHY

Samuel Chan

WHAT A PATIENT WANTS: A CONSUMER PERSPECTIVE OF KIDNEY SUPPORTIVE CARE

Louise Purtell

THE IMPACT OF DE NOVO VASCULAR DISEASE IN LIVE DONOR KIDNEY TRANSPLANT RECIPIENTS

Rahul Mainra

CUMULATIVE RADIATION EXPOSURE AMONGST RENAL REPLACEMENT THERAPY PATIENTS IN THE NORTHERN TERRITORY – A RETROSPECTIVE COHORT STUDY

Mohd Azlan Mohd Hashim

PARTICIPANT CHOICES TOWARDS RECEIVING POTENTIAL INCIDENTAL GENETIC FINDINGS IN AN AUSTRALIAN NEPHROLOGY RESEARCH GENOMICS STUDY

Andrew Mallett

VACCINE PREVENTABLE DISEASE IN IMMUNOSUPPRESSED PEOPLE WITH KIDNEY DISEASE

Alison Graver

ELICITING THE PRIORITIES OF PATIENTS, CAREGIVERS AND HEALTH PROFESSIONALS FOR IMPORTANT OUTCOMES IN NEPHROLOGY USING INTERNATIONAL BEST-WORST SCALING SURVEYS

Martin Howell

1745 Sessions Close

1900 till late

ANZSN ASM Sunset Dinner DCC ForecourtFull delegates inclusive, additional tickets can be purchased for guests and day delegates for $160. Bookings essential!


WEDNESDAY 6TH SEPTEMBER 2017 – ANZSN ASM 20170800 Registration Desk Open Concourse,

Ground Level, DCC

0800 Speakers Preparation Room Meeting Room 4 Ground Level, DCC

Seminar 4 – Clinical ScienceAuditorium 2

Indigenous Patient Voices Symposium

Meeting Room 2, Ground Level

Chairs: Jaqui Hughes & Steve May

0830-0900 BK INFECTION IN KIDNEY TRANSPLANT RECIPIENTS

Basu Gopal*

PATIENTS & CARERS YARNING CIRCLE

(closed session: clinicians/policymakers not invited)• Welcome to Country• Introductions• Sharing stories• Understanding common themes (facilitated)• What is to be presented?Proudly supported by Kidney Health Australia and Astellas.

0900-0930 FINDINGS FROM THE HEMODIALYSIS FISTULA STUDY

Laura Dember

0930-1100 ANZPNA AGM | Meeting Room 3

Plenary 3Auditorium 2

Chair: Kevan Polkinghorne

0930-1030 Plenary Speaker: Charmaine LokINSIGHTS AND INNOVATION IN VASCULAR ACCESS

1030-1130 Substantial Brunch Exhibition Area, Hall 2-3 Ground Level, DCC

1130 ASM ends. Exhibition Bump-Out Commences


PR

OG

RA

M

Paediatric Nephrology Update CourseMeeting Room 3, Ground Level

Indigenous Patient Voices SymposiumMeeting Room 2, Ground Level

1200-1215 Registration & Welcome Dr Joshua Kausman President of ANZPNA

1100-1300 Presentations by Patients and/or Carers15 minutes each (open to all delegates)

1215-1245 EVIDENCE BASED MANAGEMENT OF NEPHROTIC SYNDROME IN CHILDREN

Dr Steven McTaggart Lady Cilento Children’s Hospital, Brisbane

1245-1330 THE DIAGNOSIS AND MANAGEMENT OF HAEMOLYTIC UREMIC SYNDROME IN 2017

Dr Joshua Kausman The Royal Children’s Hospital, Melbourne

1300-1330 Break 1 Concourse

1330-1400 CONGENITAL ANOMALIES OF THE KIDNEY AND URINARY TRACT: RED FLAGS AND CALLING CRITERIA

Dr Sean Kennedy, University of New South Wales, Sydney

1330-1500 Facilitated discussion of themes arising from patient/carer presentations, with clinician & policy maker input.

1400-1415 Break Concourse

1415-1445 ACUTE POST STREPTOCOCCAL GLOMERULONEPHRITIS: UPDATE ON CHANGING EPIDEMIOLOGY AND ACUTE MANAGEMENT

Dr Swasti Chaturvedi, Royal Darwin Hospital, Darwin

1500-1530 Break 2 Concourse

* APSN SPEAKER


1445-1515 WHAT’S CURRENT IN CHILDHOOD SLE?

Dr Fiona Mackie, Sydney Children’s Hospital, Sydney

1530-1700 Facilitated “solutions brainstorming” discussion (all involved)

1515-1545 CHILDHOOD DETERMINANTS OF ADULT KIDNEY DISEASE

Dr Gurmeet Singh, Menzies School of Health Research, Darwin

1545-1645 Case Based DiscussionsRegistrants and speakers

1700 Meeting Closes 1700-1730 Travel to NT Parliament House

1730-1900 Parliamentary Reception with NT Minister for Health, Natasha Fyles MLANT Parliament House

Australian and New Zealand Society of Oaks Elan Interventional Nephrology (ANZSIN) Meeting

Wednesday 6 to Friday 8 September 2017 Oaks Elan, Darwin


PASSWORD: anzsnasm

C

M

Y

CM

MY

CY

CMY

K

HDF_Performance_And_Beyond_A4_Portrait.pdf 1 14/08/2017 3:40:55 PM


ACUTE KIDNEY INJURY

01 GEMCITABINE INDUCED HEMOLYTIC URAEMIC SYNDROME SUCCESSFULLY TREATED WITH ECULIZUMAB – A CASE REPORT

Muralikrishna Gangadharan Komala

02 UNUSUAL PRESENTATION OF BILATERAL RENAL ARTERY STENOSIS AS ANURIC RENAL FAILURE WITH SUCCESSFUL STENTING

Geoff Harley

03 EPIDEMIOLOGY AND COSTS OF MANAGEMENT OF ACUTE KIDNEY INJURY IN A TERTIARY CARE CENTER IN AUSTRALIA

Sanjeeva Herath

04 SOFA COAGULATION SCORE AND PATIENT OUTCOMES IN SEVERE ACUTE KIDNEY INJURY: ANALYSIS FROM THE RANDOMISED EVALUATION OF NORMAL VERSUS AUGMENTED LEVEL (RENAL) STUDY

Jin Lin

05 RENAL CONSULT AUDIT AT A TERTIARY REFERRAL HOSPITAL Charlotte Ogilvy

06 A CASE OF ACUTE KIDNEY INJURY AND THROMBOTIC MICROANGIOPATHY SECONDARY TO UROTHELIAL CANCER AND THE IMPACT OF TREATMENT ON THE DISEASE PROCESS

Ben Talbot

07 “UNEARTHING” THE CAUSE OF ACUTE KIDNEY INJURY IN A GARDENER

Jeffrey Wong

08 PATIENT-DERIVED ENDOTHELIAL CELL FUNCTION IS PREDICTED BY CONTROLLED BLOOD PRESSURE

Brooke Huuskes

09 RATES AND CHARACTERISTICS OF ACUTE KIDNEY INJURY (AKI) IN THE CHRONIC KIDNEY DISEASE IN QUEENSLAND (CKD.QLD) REGISTRY

Gregory Wilson

10 ETHYLENE GLYCOL TOXICITY – A RARE CAUSE OF HIGH ANION GAP METABOLIC ACIDOSIS IN AUSTRALIA

Gregory Wilson

EPIDEMIOLOGY AND PUBLIC HEALTH

11 ACUTE INTERSTITIAL NEPHRITIS (AIN) IN AUSTRALIA: A SINGLE CENTRE CASE SERIES

Gregory Wilson

12 TRAJECTORIES OF EGFR DECLINE OVER A FOUR YEAR PERIOD: THE EGFR FOLLOW UP STUDY

Federica Barzi

POSTERS


PO

STE

RS

13 EVALUATING ASSOCIATIONS OF BODY MASS INDEX (BMI) IN CHRONIC KIDNEY DISEASE PATIENTS (CKD) IN THE CKD.QLD REGISTRY; QUEENSLAND, AUSTRALIA

Samuel Chan

14 DEATH FROM STROKE IN THE ESKD POPULATION; A COHORT STUDY IN AUSTRALIA AND NEW ZEALAND, 1980-2013

Nicole L De La Mata

15 KNOWLEDGE ABOUT CHRONIC KIDNEY DISEASE IN THE AUSTRALIAN PUBLIC, USING A NEW VALIDATED QUESTIONNAIRE

Pankti Gheewala

16 ELDERLY DIALYSIS PATIENTS AND QUALITY OF LIFE: A SINGLE CENTRE EXPERIENCE

Krystal Harrison

17 DISTANCE TO HUB RENAL SERVICE AND OUTCOMES OF PATIENTS WITH STAGE IV-V CHRONIC KIDNEY DISEASE

Prasanti Kotagiri

18 KIDNEY DISEASE IN INCARCERATED TASMANIANS Stephanie Kuo

19 ATTAINMENT OF HEMOGLOBIN, CALCIUM AND PHOSPHATE TARGETS, MORTALITY AND TIME TO TRANSPLANT IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS IN AUSTRALIA

Dhanusya Sivanthanan

20 RENAL MARKERS AT BASELINE IN THE HEALTHTRACK STUDY- A RANDOMISED CONTROL TRIAL OF INTERDISCIPLINARY CARE ON WEIGHT LOSS

Maureen Lonergan

21 SALT WASTING NEPHROPATHY(SWN) – IMPORTANT QUESTIONS

Rishi Narenthiran

22 SALT WASTING NEPHROPATHY(SWN) IN PRIMARY CARE Rishi Narenthiran

23 THE PREVALENCE OF NON-DIABETIC PATHOLOGY IN THE RENAL BIOPSIES OF PATIENTS WITH DIABETES IN FAR NORTH QUEENSLAND

Lee Skeat

24 CHARACTERISTICS, MORTALITY AND RENAL OUTCOMES OF PATIENTS WITH DIABETES AND CKD WHO HAVE UNDERGONE RENAL BIOPSY.

Samantha Ng

25 A SINGLE CENTRE EXPERIENCE OF RENAL CALCULI IN CENTRAL AUSTRALIA

Sajan Thomas

26 THE PREVALENCE OF CHRONIC KIDNEY DISEASE AND ACUTE KIDNEY INJURY AMONGST ADULT ACUTE INPATIENTS AT MONASH HEALTH.

Dan Tran

27 CKD.QLD: RELATIONSHIP BETWEEN SMOKING AND CHRONIC KIDNEY DISEASE (CKD) IN THE DARLING DOWNS REGION, QUEENSLAND.

Wendy Hoy


28 PREVALENCE AND SEROCONVERSION OF HEPATITIS C VIRUS AMONG HEMODIALYSIS PATIENTS IN PEMALANG,INDONESIA

Muchamad Nur Aziz

29 APPROPRIATENESS OF NEPHROLOGY REFERRALS IN REGIONAL AUSTRALIA: IMPLICATIONS FOR A SPECIALIST SERVICE

Rebecca Thwaites

30 MEDICATION BURDEN, ADHERENCE AND HEALTH-RELATED QUALITY OF LIFE IN ADVANCED CHRONIC KIDNEY DISEASE

Wubshet Tesfaye

CARDIOVASCULAR/HYPERTENSION

31 SUDDEN SEVERE HYPERTENSION: AN ATYPICAL MANIFESTATION OF PRIMARY HYERPARATHYROIDISM. A CASE REPORT

Claudia Ferrier

32 RENAL ARTERY STENOSIS AS A CAUSE OF TAKOTSUBO CARDIOMYOPATHY

Victoria Sasongko

33 FIRST CARDIOVASCULAR EVENT POST ENROLMENT IN CKD.QLD REGISTRY PATIENTS WITH DIABETES WHO HAVE UNDERGONE RENAL BIOPSY

Ken-soon Tan

34 HIGH-SENSITIVITY CARDIAC TROPONIN T AND C-REACTIVE PROTEIN HAVE DIFFERENT PROGNOSTIC VALUES IN HAEMO- AND PERITONEAL DIALYSIS POPULATION: A COHORT STUDY

Titi Chen

GLOMERULONEPHRITIS

35 RENAL CD141+ DENDRITIC CELLS INFILTRATION IN CRESCENTIC GLOMERULONEPHRITIS IN HUMAN AND MICE

Padmashree Rao

36 RENAL CD141+ DENDRITIC CELL INFILTRATION IN IGA NEPHROPATHY

Padmashree Rao

37 COMPLICATED ATRIAL THROMBUS IN RENAL TRANSPLANT RECIPIENT WITH RECURRENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Nyi Aung

38 PREVALENCE OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE IN PATIENTS UNDERGOING DIAGNOSTIC RENAL BIOPSY

Ke Li Chow

39 A CASE REPORT OF HENOCH-SCHONLEIN PURPURA AND IGA NEPHROPATHY ASSOCIATED WITH RIVAROXABAN

Edmund Chung

40 A CASE OF ANTI-GBM BEHAVING DIFFERENTLY Sanduni Fernando

41 A CASE OF METHAMPHETAMINE-RELATED IMMUNE COMPLEX GLOMERULONEPHRITIS WITH INTENSE INTERSTITIAL INFLAMMATION

Sarah Gleeson


PO

STE

RS

42 OTITIS MEDIA WITH ANCA – ASSOCIATED VASCULITIS: A CASE FROM TASMANIA

Alison Graver

43 CLINICAL AUDIT OF HISTOLOGY BASED RENAL DISEASES IN DARLING DOWNS HEALTH REGION

Vinod Khelgi

44 MEMBRANOUS NEPHROPATHY AND MALIGNANCY-A REPORT FROM DARLING DOWNS HOSPITAL AND HEALTH SERVICE

Vinod Khelgi

45 PREVALENCE OF ANCA VASCULITIS IN DDHHS POPULATION Vinod Khelgi

46 THE MAN WHO ‘CRIED’ WOLF: CRYOGLOBULINEMIC GLOMERULONEPHRITIS ASSOCIATED WITH T CELL LYMPHOMA

Jennifer Li

47 PARANEOPLASTIC IMMUNOGLOBULIN A NEPHROPATHY AND ASSOCIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS IN ASYMPTOMATIC LOW VOLUME B-CELL LYMPHOMA

Andrew Mallett

48 C1Q DEPOSITION IN A CASE SERIES OF CHILDREN WITH HENOCH-SCHÖNLEIN PURPURA AND POSITIVE STREPTOCOCCAL SEROLOGY

Ashlene Mckay

49 JEJUNAL ULCERATION DUE TO GRANULOMATOSIS WITH POLYANGITIS

Daniela Potter

50 ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE AND THE EYE

Daniela Potter

51 IGA-MEDIATED ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE

Amanda Siriwardana

52 A RETROSPECTIVE ANALYSIS OF LUPUS NEPHRITIS IN THE INDIGENOUS AND NON-INDIGENOUS POPULATIONS IN THE NORTHERN TERRITORY: TREATMENT, OUTCOMES AND CHALLENGES

Priyanka Subramani

53 WARFARIN VS NEW ORAL ANTICOAGULANT IN PRIMARY ADULT NEPHROTIC SYNDORME ASSOCIATED VENOUS THORMBOEMBOLISM

Zaw Thet

54 HAEM PIGMENT-INDUCED CHRONIC KIDNEY DISEASE IN A PATIENT WITH GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY

Marina Wainstein

55 ACUTE POST-STREPTOCOCCAL GLOMERULONEPHRITIS- A CASE REPORT AND EPIDEMIOLOGICAL DATA FROM THE NORTHERN TERRITORY OF AUSTRALIA

Swasti Chaturvedi

56 SYSTEMIC LUPUS ERYTHEMATOSUS MASQUERADING AS ATYPICAL HAEMOLYTIC URAEMIC SYNDROME

Stephanie Kuo


57 PULMONARY FIBROSIS IN RENAL ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) ASSOCIATED VASCULITIS IN TASMANIA OVER A 10 YEAR PERIOD

Stephanie Kuo

HEALTH SERVICES RESEARCH

58 MANAGEMENT OF MEDICATIONS IN PEOPLE WITH CHRONIC KIDNEY DISEASE

Stephanie Kuo, Alison Graver

59 ADVANCED CARE PLANNING IN END-STAGE KIDNEY DISEASE – WE CAN DO BETTER

Margaret Fraenkel

60 ANALYSIS OF LONGITUDINAL CLINICAL DATA TO EVALUATE CHANGES IN THE SCREENING FOR AND MANAGEMENT OF CKD IN SELECT NT PRIMARY HEALTH SERVICES.

Gillian Gorham

61 CHRONIC KIDNEY DISEASE (CKD) AND HEALTH CARE UTILISATION: INSIGHTS FROM HEALTH DATA LINKAGE IN QUEENSLAND

Wendy Hoy

62 PRELIMINARY RESULTS OF AN ECONOMIC EVALUATION OF RESONIUM USE IN ADULTS WITH CHRONIC HYPERKALEMIA

Kelly Lambert

63 DO NORTHERN TERRITORY PATIENTS GET HOME? ANALYSIS THROUGH THE DIALYSIS MODELS OF CARE PARTNERSHIP

Paul Lawton

64 DEVELOPING AN IMPROVED MODEL OF CARE FOR RENAL OUTPATIENTS IN THE NORTHERN TERRITORY (NT)

Kelum Priyadarshana

GENERAL NEPHROLOGY – OTHER

65 RENAL AMYLOIDOSIS: IT’S NOT ALL AL Emily Butler

66 CHRONIC USE OF SODIUM POLYSTYRENE SULFONATE (RESONIUM) ENABLES WIDER IMPLEMENTATION OF RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITION IN CHRONIC KIDNEY DISEASE PATIENTS

Kelly Lambert

67 LIRAGLUTIDE FACILITATES INSULIN MINIMISATION AND WEIGHT LOSS IN PATIENTS WITH ADVANCED KIDNEY DISEASE

Jamie Cheong

68 EFFICACY AND SAFETY OF A MEMBRANE BASED REGIONAL CITRATE ANTICOAGULATION PLASMA EXCHANGE PROTOCOL: AN OBSERVATIONAL, PROSPECTIVE, SINGLE CENTER STUDY

Daniel Christiadi

69 PRE-OPERATIVE EGFR AND LENGTH OF POST-OPERATIVE HOSPITALISATION IN TUMOUR NEPHRECTOMY PATIENTS

Robert Ellis

70 THE UPS AND DOWNS OF BARIATRIC SURGERY: A CASE OF REVERSIBLE OXALATE NEPHROPATHY

Alexandra Gallagher

71 AN AUDIT OF RENAL BIOPSY COMPLICATIONS Alison Graver


PO

STE

RS

72 HEPCIDIN RESPONSE TO IV IRON IS DIFFERENT IN CHRONIC KIDNEY DISEASE PATIENTS COMPARED WITH PREGNANCY AND HEALTHY CONTROLS

Louis Huang

73 DENOSUMAB INDUCED HYPOCALCAEMIA IN CHRONIC KIDNEY DISEASE (CKD): PREVENTION IS BETTER THAN TREATMENT

Ryan Jalleh

74 CASE SERIES OF CALCIPHYLAXIS AT DDHHS: SINGLE CENTRE EXPERIENCE

Vinod Khelgi

75 SEROCONVERSION RATES OF HEPATITIS B IN CHRONIC KIDNEY DISEASE AND DIALYSIS COHORTS- A SINGLE CENTRE OBSERVATIONAL STUDY.

Ashani Lecamwasam

76 DNA METHYLATION PROFILING OF GENOMIC DNA ISOLATED FROM URINE IN DIABETIC CHRONIC KIDNEY DISEASE: A PILOT STUDY

Ashani Lecamwasam

77 ENDOTHELIAL GLYCOCALYX DAMAGE IN KIDNEY DISEASE CORRELATES WITH MARKERS OF ENDOTHELIAL DYSFUNCTION

Hui Liew

78 ACUTE RENAL FAILURE, RASH AND DIFFUSE PROLIFERATIVE GLOMERULONEPHRITIS FOLLOWING THREE DOSES OF ETANERCEPT FOR RHEUMATOID ARTHRITIS

Maureen Lonergan

79 A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE USEFULNESS OF GLYCATED HAEMOGLOBIN (HBA1C) AND GLYCATED ALBUMIN AS MEASURES OF BLOOD GLUCOSE LEVELS IN PEOPLE WITH ON DIALYSIS

Sandawana William Majoni

80 RELATIVE VALIDITY OF A BEVERAGE FREQUENCY QUESTIONNAIRE TO ESTIMATE FLUID INTAKE IN CHRONIC KIDNEY DISEASE.

Carly Mannix

81 UNPROVOKED PULMONARY EMBOLISM IN A RENAL TRANSPLANT PATIENT WITH BETA THALASSAEMIA MAJOR

Cathal McGowan

82 COMPLEXITIES OF SYMPTOM MANAGEMENT AND PROGNOSTICATION IN A CASE OF CONSERVATIVELY MANAGED END-STAGE KIDNEY DISEASE (ESKD)

Simon Olenski

83 ESTABLISHING A CHRONIC KIDNEY DISEASE BIOBANK IN QUEENSLAND TO SUPPORT FUTURE RESEARCH

Evan Owens

84 THE DISTINGUISHING RISK OF PROGRESSIVE CHRONIC KIDNEY DISEASE (DROP CKD) STUDY

Evan Owens

85 A CASE OF EVOLVING LUPUS PRESENTING AS REFRACTORY THROMBOTIC MICROANGIOPATHY

Theepika Rajkumar


86 OBSERVATIONAL CROSS SECTIONAL STUDY INVESTIGATING THE PREVALENCE OF FABRY DISEASE IN CHRONIC STABLE DIALYSIS POPULATION (FIDS).

Gowri Raman

87 THE DIAGNOSIS AND MANAGEMENT OF TAKAYASU’S ARTERITIS IN A REGIONAL SETTING

Joey Lam

88 EVALUATION OF PAIN IN RENAL INTERVENTIONS Victoria Sasongko

89 HEALTH LITERACY IN A SINGLE SITE RENAL SUPPORTIVE CARE CLINIC

Jessica Stevenson

90 SEVERE HYPONATRAEMIA, BEER POTOMANIA AND RHABDOMYOLYSIS

Robert Stonehouse

91 UPDATE ON HOW TELEHEALTH REVOLUTIONISED RENAL HEALTHCARE DELIVERY IN WAIKATO HOSPITAL, NEW ZEALAND

Eddie Tan, Theresa Jennings

92 RENAL TUBERCULOSIS AFTER INTRAVESCIAL BACILLE CALMETTE- GUERIN (BCG) IMMUNOTHERAPY

Zaw Thet

93 INTERIM ANALYSIS OF FABRY TESTING IN WESTERN AUSTRALIA RENAL DIALYSIS PATIENTS: THE FORWARD STUDY

Shamina Akhter

94 DIABETIC MYONECROSIS IN DIABETIC KIDNEY DISEASE Nicholas Trott

95 “INTERVENTIONAL DAY UNIT” – A SOUTH WESTERN SYDNEY LOCAL HEALTH DISTRICT (SWSLHD) OUTPATIENT SERVICE INITIATIVE. REDESIGNING RENAL SERVICE DELIVERY

Jeff Wong

96 THE USUAL DIET OF AN AUSTRALIAN POPULATION OF ADPKD PATIENTS

Jennifer Zhang

97 INFLUENCE OF TIMING AND PATIENT CHARACTERISTICS ON OUTCOMES OF A COMPREHENSIVE PRE-DIALYSIS PROGRAMME IN WESTERN SYDNEY

Lukas Kairaitis

98 TOTAL NEPHRON NUMBER DECREASES WITH THE STAGE OF CHRONIC KIDNEY DISEASE – A STUDY IN JAPANESE SUBJECTS

Go Kanzaki

99 CHARACTERISTICS OF THE SCREENED STUDY POPULATION IN THE PREVENT-ADPKD TRIAL

Annette Wong

HAEMODIALYSIS – CKD-MBD/ANAEMIA/ADEQUACY

100 INDIVIDUALISED FLUID ALLOWANCE CALCULATOR FOR HAEMODIALYSIS PATIENTS

Shi Zhou Choo

101 BROWN TUMOURS MANIFESTING AS MULTIPLE LYTIC LESIONS IN A GENTLEMAN ON DIALYSIS WITH LONGSTANDING UNCONTROLLED HYPERPARATHYROIDISM

Geoff Harley


PO

STE

RS

102 IS THE EFFICACY OF NUTRITIONAL VITAMIN D (CHOLECALCIFEROL) COMPARABLE TO ACTIVE VITAMIN D (CALCITRIOL) AS MAINTENANCE THERAPY IN DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE PATIENTS?

Chau Wang Ng

103 MARKED REDUCTION IN USE BUT MINIMAL IMPACT FOLLOWING PBS DELISTING OF CINACALCET IN A TERTIARY INSTITUTION

Yogeshwar Rajaram

104 RETROSPECTIVE OBSERVATIONAL STUDY COMPARING TWO ANAEMIA MANAGEMENT PROTOCOLS FOR PATIENTS ON MAINTENANCE HAEMODIALYSIS

David Langsford

HAEMODIALYSIS – OTHER

105 ELECTROCARDIOGRAPHY (ECG) AND OUTCOME IN PATIENTS ON MAINTENANCE HAEMODIALYSIS

Tony Amin

106 THE VICTORIAN GREENS SURVEY: GAUGING RESPONSES TO ENVIRONMENTAL EFFICIENCIES IN NEPHROLOGY SERVICES

Katherine Barraclough

107 SUCCESSFUL CALCIPHYLAXIS TREATMENT WITH PARENTERAL VITAMIN K

Daniel Christiadi

108 PREVALENCE OF MALNUTRITION AMONGST HAEMODIALYSIS PATIENTS ATTENDING NIGHTCLIFF RENAL UNIT

Christine Cooper

109 EVALUATION OF NUTRITION RESOURCES TARGETED AT AN INDIGENOUS AUDIENCE

Camilla Feeney

110 COMPARING BIOIMPEDENCE SPECTROSCOPY FLUID BALANCE ASSESSMENT TO CLINICAL FLUID BALANCE ASSESSMENT IN HAEMODIALYSIS PATIENTS

Sarah Gleeson

111 LOW RATES OF HEPATITIS B IMMUNITY IN CENTRE HAEMODIALYSIS PATIENTS

Hilton Gock

112 DELAYED RESOLUTION OF AN EXTENSIVE DERMATOPHYTE INFECTION: CLIENT AND CLINICIAN PERCEPTIONS OF TREATMENT RESPONSE IN AN ADULT DEPENDENT ON HAEMODIALYSIS

Jaquelyne Hughes

113 CHARACTERISTICS OF CLIENTS AT INCIDENT HAEMODIALYSIS TREATMENT: A RETROSPECTIVE AUDIT IN A NORTHERN AUSTRALIAN HOSPITAL

Jaquelyne Hughes

114 THE EFFECT OF INTENSIFIED HOME HAEMODIALYSIS TRAINING: A SINGLE CENTRE EXPERIENCE

Graham Stonier, Eddie Tan


115 A LOCAL EXPERIENCE OF HOW TELEHEALTH REVOLUTIONISED THE ROLE OF RURAL RENAL NURSING

Theresa Jennings, Eddie Tan

116 A SINGLE-CENTRE 12-MONTH RETROSPECTIVE AUDIT OF SATELLITE HAEMODIALYSIS PATIENT ATTENDANCE AND UNUSUED SLOTS

Theresa Jennings

117 THE STANDARDISED OUTCOMES IN NEPHROLOGY-HAEMODIALYSIS (SONG-HD) CONSENSUS WORKSHOP ON ESTABLISHING A CORE OUTCOME MEASURE FOR FATIGUE IN PATIENTS ON HAEMODIALYSIS

Angela Ju

118 IS THERE ANY BENEFIT OF SEASONAL INFLUENZA VACCINATION IN DIALYSIS POPULATION ?

Jola Kapojos

119 ZINC DEFICIENCY AND ASSOCIATED FACTORS IN A COHORT OF HAEMODIALYSIS PATIENTS

Jocelyn King

120 ASSISTED SELF-CARE HAEMODIALYSIS COMPARED TO IN-CENTRE HAEMODIALYSIS – A SINGLE CENTRE EXPERIENCE

Jason Lee

121 THE SYNDROME OF ACUTE BILATERAL BASAL GANGLIA DYSFUNCTION IN DIALYSIS PATIENTS – RISK FACTORS, PRESENTATION AND OUTCOMES

Revathy Manickavasagar

122 “A CHANGE OF HEART”: A CASE SERIES ANALYSIS OF END STAGE KIDNEY DISEASE PATIENTS CHANGING FROM CONSERVATIVE TO ACTIVE DIALYSIS TREATMENT.

Katherine Nguyen

123 PNEUMATIC COMPRESSION DEVICES IN THE PREVENTION OF INTRADIALYTIC HYPOTENSION

Huan Dang, Christopher Sia

124 IS DIABETIC MYONECROSIS MORE COMMON THAN WE THOUGHT? A CLUSTER OF CASES IN PATIENTS WITH END STAGE KIDNEY DISEASE IN CENTRAL AUSTRALIA

Priyanka Subramani

125 HIGH-DOSE INTRAVENOUS METHOTREXATE WITH HIGH-FLUX HAEMODIALYSIS IN TREATMENT OF POST-TRANSPLANT, CENTRAL NERVOUS SYSTEM LYMPHOMA WITH END-STAGE KIDNEY DISEASE

Erin Vaughan

126 AN UNUSUAL CASE OF HYPERCALCAEMIA IN A HAEMODIALYSIS PATIENT

Catherine Wilkinson

127 CONTACT PRECAUTIONS FOR COLONISATION WITH MULTI-DRUG REISTANT ORGANISMS AND HAEMODIALYSIS PATIENT QUALITY OF LIFE AND MOOD: A PILOT CASE CONTROL STUDY

Catherine Wilkinson

128 GASTROINTESTINAL SYMPTOMS IN PATIENTS RECEIVING DIALYSIS: A SYSTEMATIC REVIEW

Jordan Zuvela


PO

STE

RS

HAEMODIALYSIS – VASCULAR ACCESS

129 CLINICAL OUTCOMES OF PERCUTANEOUS THROMBECTOMY OF DIALYSIS ACCESS THROMBOSIS BY NEPHROLOGISTS IN CENTRAL AUSTRALIA

David Kiran Fernandes

130 REPORTING FEASIBILITY OF THE USE OF A REAL-TIME DATA REPORTING TOOL TO IMPROVE OUTCOMES OF HAEMODIALYSIS CATHETER COMPLICATIONS ACROSS AUSTRALIA (REDUCCTION)

Sradha Kotwal

131 REVIEW OF ANTI-MICROBIAL RESISTANT ORGANISMS CAUSING VASCULAR ACCESS ASSOCIATED BACTERAEMIA IN HAEMODIALYSIS PATIENTS IN 2015-2016

Laila Parvaresh

132 USE OF A CLINICAL SCORING TOOL IN PREDICTING ARTERIOVENOUS FISTULAS LIKELY TO FAIL TO MATURE

Tahira Scott

133 ROLE OF SERUM GENTAMICIN LEVEL TESTING IN HAEMODIALYSIS PATIENTS RECEIVING GENTAMICIN LOCKS FOR TUNNELED VENOUS CATHETERS

Jacqueline Soraru

134 OMEGA-3 PUFA SUPPLEMENTATION TO PREVENT ARTERIOVENOUS FISTULA AND GRAFT FAILURE: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

Andrea Viecelli

135 VASCULAR ACCESS IN PATIENTS COMMENCING HAEMODIALYSIS – RESULTS OF IMPLEMENTATION OF A QUALITY IMPROVEMENT PROJECT

Tamara Young

PAEDIATRICS

136 THE MULTIDISCIPLINARY PAEDIATRIC RENAL GENETICS CLINIC: A MODEL FOR MAINSTREAMING GENETICS IN MEDICINE

Andrew Mallett

PERITONEAL DIALYSIS

137 CULTURE-INDEPENDENT IDENTIFICATION OF BACTERIA CAUSING PERITONEAL DIALYSIS ASSOCIATED PERITONITIS

Aron Chakera

138 DEVELOPING AN ASSISTED AUTOMATED PERITONEAL DIALYSIS PROGRAM IN WESTERN AUSTRALIA

Aron Chakera

139 RAPID ASSESSMENT OF BACTERIAL LOAD AND RESISTANCE PHENOTYPE IN PERITONEAL DIALYSIS EFFLUENT BY FLOW CYTOMETRY

Aron Chakera

140 AN UNUSUAL CASE OF CATHETER MIGRATION IN A PERITONEAL DIALYSIS PATIENT

Shyamalee Crocker


141 USE OF DEFERASIROX (EXJADE) FOR IRON OVERLOAD IN PERITONEAL DIALYSIS PATIENTS.

Erwin Yii

142 CLOUDY BAG: NOT ALWAYS PERITONITIS Vinod Khelgi

143 MORGANELLA MORGANII PD-RELATED PERITONITIS IN A LUNG TRANSPLANT PATIENT

Alice Lee

144 PERITONEAL DIALYSIS CATHETERS FOR RECURRENT/REFRACTORY ASCITES DRAINAGE

Eddie Tan

145 RETAINED PERITONEAL DIALYSIS CATHETER TUNNELING DEVICE SEGMENT ASSOCIATED WITH RECURRENT PERITONITIS: A CASE REPORT

Beata Zahorowska

146 GASTROINTESTINAL MUCORMYCOSIS IN A PERITONEAL DIALYSIS PATIENT WITH END STAGE RENAL FAILURE SECONDARY TO AA AMYLOIDOSIS: A CASE REPORT

Beata Zahorowska

TRANSPLANTATION

147 DETECTION OF HEPATITIS C ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS FROM A DECEASED DONOR PREVIOUSLY TREATED FOR HEPATITIS C

Neeru Agarwal

148 A RETROSPECTIVE STUDY OF DONOR NEPHRECTOMY ON RENAL FUNCTION AND APPLICATION OF LIVING KIDNEY DONOR PROFILE INDEX (LKDPI)

Nyi Aung

149 FLUDROCORTISONE IN THE MANAGEMENT OF TUBULOPATHIES POST-RENAL TRANSPLANTATION

Shyamalee Crocker

150 THROMBOLYSIS FOR PULMONARY EMBOLISM EARLY POST-RENAL TRANSPLANTATION

Shyamalee Crocker

151 COMPUTED TOMOGRAPHY CORONARY ANGIOGRAPHY USE IN END STAGE RENAL FAILURE

Sarah Gleeson

152 THE SYMPTOM BURDEN OF TRANSPLANT PATIENTS COMPARED TO DIALYSIS PATIENTS

Jeffrey Ha

153 EXPECTATIONS AND EXPERIENCES OF FOLLOW UP AND SELF-CARE AFTER LIVING KIDNEY DONATION: A FOCUS GROUP STUDY

Camilla Hanson

154 EARLY GRAFT LOSS DUE TO RECURRENCE OF DIABETIC NEPHROPATHY FOLLOWING LIVE DONOR KIDNEY TRANSPLANTATION

Jack Heron

155 BACILLARY ANGIOMATOSIS IN A RENAL TRANSPLANT RECIPIENT

Vinod Khelgi


PO

STE

RS

156 NON-ABO RED BLOOD CELL GROUP ANTIGENS IN RENAL TRANSPLANTATION

Prasanti Kotagiri

157 THE ADOPT TRIAL: A PHARMACOMETRIC STUDY OF THE BETWEEN-OCCASION VARIABILITY IN FREE MYCOPHENOLIC ACID PHARMACOKINETICS PRIOR TO AND IN THE EARLY PHASE POST KIDNEY TRANSPLANT IN SIXTY PROSPECTIVELY RECRUITED ADULTS AND CHILDREN

David Metz

158 RHABDOMYOLYSIS SECONDARY TO SEASONAL INFLUENZA VACCINE IN A RENAL TRANSPLANT RECIPIENT

Amanda Siriwardana

159 SCEDOSPORIUM APIOSPERMUM BONE INFECTION IN A RENAL TRANSPLANT RECIPIENT

Amanda Siriwardana

160 RESISTANT CYTOMEGALOVIRUS DISEASE IN KIDNEY-PANCREAS TRANSPLANT: TREATMENT WITH PRIMED T-CELL THERAPY

Sarah So

161 SPONTANEOUS ATRAUMATIC SPLENIC RUPTURE FOLLOWING INTRAVENOUS IMMUNOGLOBULIN FOR PARVOVIRUS B19 ASSOCIATED PURE RED CELL APLASIA IN A RENAL TRANSPLANT PATIENT – A CASE REPORT

Mark Tiong

162 POST RENAL TRANSPLANT EXTRAPULMONARY TUBERCULOSIS IN AN OVERSEAS-BORN AUSTRALIAN

Catherine Wilkinson

163 TEMPORAL TRENDS IN CLINICAL OUTCOMES OF KIDNEY TRANSPLANTATION FROM 1996 TO 2013 IN AUSTRALIA AND NEW ZEALAND

Wing Chi Gigi Yeung

164 CORRELATION AND AGREEMENT BETWEEN THE NUMBER OF CLASS I AND II EPLET MISMATCHES CALCULATED USING SEROLOGICAL, LOW-INTERMEDIATE AND HIGH RESOLUTION MOLECULAR HUMAN LEUKOCYTE ANTIGEN TYPING METHODS

Wai Lim

165 MORTALITY FOLLOWING PRIMARY RENAL ALLOGRAFT FAILURE – A REGISTRY ANALYSIS

Wai Lim


PASSWORD: anzsnasm


LOADING DOCK

ANZSN 2017POSTERS FLOORPLAN

ENTRY/EXIT

FOYER

08

BARISTA CAFE

17

REGISTRATION

18

19

16

15

070605

#01#02 #03 #04 #05 #06 #07

#20 #19 #18

#37 #36 #35 #34

#46 #45 #44 #43 #42

#28 #27 #26 #25 #24

#21 #22 #23

#29 #30 #31#32 #33

#38 #39 #40#41

#47 #48 #49#50 #51

#72 #73 #74#75 #76 #77

#78 #79 #80#81 #82 #83

#89 #88 #87#86 #85 #84

#95 #94#93 #92 #91 #90

#132 #131 #130 #129 #128 #127 #126 #125#124 #123 #122 #121

#137 #138 #139 #140 #141 #142

#154 #155 #156 #157 #158 #159

#160 #161 #162 #163 #164 #165

#151 #152 #153

#148 #147 #146 #145 #144 #143

#08#09 #10 #11 #12 #13 #14#15 #16 #17

#52#53#54#55#56 #57#58#59#60#61#62#63#64#65#66#67#68 #69 #70 #71

04 09

10

11

121314

03

02

01

#96#97 #98 #99 #100

#133#134 #135 #136

#149#150

#107#106#105 #104 #103 #102

#108#109#110 #111 #112 #113

#114#115#116 #117 #118 #119 #120

#101

EXHIBITORS & POSTERS FLOORPLAN


# ORGANISATION

01 Vifor Pharma

02 Nxstage Medical

03 ANZSIN

04 AstraZeneca

05 Australasian Kidney Trials Network & ANZDATA

06 KHA – CARI & Cochrane Kidney Transplant

07 Kidney Health Australia

08 Western Desert Nganampa Walytja Palyantjaku Tjutaku

09 Ortho Clinical Diagnostics

10 MSD

11 Alexion Pharmaceuticals Australasia

12 Paperbark Woman

13 Novartis

14 Sanofi Australia

15 BAXTER

16 Fresenius

17 Otsuka Australia Pharmaceutical

18 Roche Products

19 AMGEN

EXHIBITORS

# Numbers indicate posters. See poster list on page 38 – 49.


–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

NOTES

DARWIN MAP

1. DOWNLOADGo to the apple store or the Android play store and search for “Conference Design”. Download the Conference Design App onto your device.

3. FIND ANZSN 2017Select the ANZSN 2017 guide from the list; this download may take a few minutes.

2. OPEN THE APP

Find and open the Conference Design App on your device. Click on download guides at the bottom of your screen.

4. EXPLORE!Open the guide and click on the menu items to browse ASM information. You can register a delegate profile to connect with others.

ANZSN 2017

www.anzsnasm.com

ANZSN ASM ASTELLAS APPWe encourage you to download our mobile guide to enhance your experience at the ANZSN ASM 2017. You’ll be able to plan your day with a personalised schedule, take notes, connect with other delegates and browse sponsors, maps and general conference information.

The app is compatible with iPhones, iPads, iPod Touches and Android devices.

53rd ANNUAL SCIENTIFIC MEETING AUSTRALIAN AND · PDF fileAUSTRALIAN AND NEW ZEALAND SOCIETY OF...

Documents

Transcript of 53rd ANNUAL SCIENTIFIC MEETING AUSTRALIAN AND · PDF fileAUSTRALIAN AND NEW ZEALAND SOCIETY OF...